1. Scrip
  2. >>New Products

Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market

Long-Acting Injectable Adds To Franchise

 
• By Jessica Merrill

Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.

wood carving
Teva looks to carve out a niche in the LAI market • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. believes it can build a sizable commercial franchise out of its newly approved long-acting antipsychotic Uzedy (risperidone). During Teva’s first quarter sales and earnings call on 10 May, CEO Richard Francis said Uzedy will be the next growth pillar in the company’s branded portfolio, anchored by Austedo (deutetrabenazine) and Ajovy (fremanezumab).

“We think this has the opportunity to grab between 10% to 20% of that $4bn market,” Francis said, referring to the size of the market for long-acting injectable drugs for schizophrenia

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.